PHARMA NORD ApS: Financial statements 2017
CVR: 67303016
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
PHARMA NORD ApS (CVR 67303016) has filed annual accounts for 2017. In 2017, the company reported revenue of DKK 343,074,000 and a net result of DKK 46,790,000 compared with DKK 62,012,000 the year before. That is an increase of 1.7% compared with the year before. The profit margin was 13.6%. Equity in the 2017 report amounted to DKK 181,881,000. The solvency ratio was 54.1%. The company had 378 employees in the financial year.
- Revenue
- DKK 343,074,000
- Gross Profit
- DKK 135,407,000
- Profit/Loss
- DKK 46,790,000
- Equity
- DKK 181,881,000
- Total Assets
- DKK 336,241,000
- Employees
- 378
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 343.1 mio. | 135.4 mio. | 46.8 mio. | 181.9 mio. | 378 |
| 2016 | 337.3 mio. | 149.4 mio. | 62 mio. | 142 mio. | 315 |
| 2015 | 417.5 mio. | 198.7 mio. | 55.8 mio. | - | 307 |
| 2014 | 317.1 mio. | 121.5 mio. | 30.2 mio. | 29.8 mio. | 285 |
| 2013 | 317.4 mio. | 98.7 mio. | 11.2 mio. | -215 t. | 275 |
Official annual report
Keep an eye on PHARMA NORD ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
PHARMA NORD ApS has published its annual report for 2016. Revenue came to DKK 337,277,000, and the net result was DKK 62,012,000.
About PHARMA NORD ApS
PHARMA NORD ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 1981. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named DANMARKS HELSEKOST DISTRIBUTION ApS. The management consists of Eli Wallin. The board consists of Michael Christiani Havemann (chair) and Eli Wallin. The company is owned by PHARMCO I ApS and PharmCo III ApS. The company has 298 employees (2026). In 2025, the company reported revenue of DKK 518,005,000 and a net result of DKK 26,711,000 compared with DKK 32,254,000 the year before. Equity in the 2025 report amounted to DKK 181,417,000.